Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still&#039;s disease

Browse by...

Deposit

Highlights

More informations

Title		Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease
Authors		Gabay, Cem Fautrel, Bruno Rech, Jürgen Spertini, François Feist, Eugen Kötter, Ina Hachulla, Eric Morel, Jacques Schaeverbeke, Thierry Hamidou, Mohamed A Martin, Thierry Hellmich, Bernhard Lamprecht, Peter Schulze-Koops, Hendrik Courvoisier, Delphine Sophie Sleight, Andrew Schiffrin, Eduardo Jorge show all authors [1 - 17]
Published in		Annals of the Rheumatic Diseases. 2018, vol. 77, no. 6, p. 840-847
Abstract		Adult-onset Still's disease (AOSD) is a rare systemic autoinflammatory disease; its management is largely empirical. This is the first clinical study to determine if interleukin (IL)-18 inhibition, using the recombinant human IL-18 binding protein, tadekinig alfa, is a therapeutic option in AOSD.
Identifiers		DOI: 10.1136/annrheumdis-2017-212608 PMID: 29472362
Full text		Article (Published version) (727 Kb) - Free access
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine
Research group		Mécanisme de l'inflammation articulaire (44)
Citation (ISO format)		GABAY, Cem et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. In: Annals of the Rheumatic Diseases, 2018, vol. 77, n° 6, p. 840-847. doi: 10.1136/annrheumdis-2017-212608 https://archive-ouverte.unige.ch/unige:110671